Semaglutide is indicated for adults with type 2 diabetes mellitus (T2DM) who are receiving metformin and/or sulfonylureas in addition to diet control and exercise and whose blood glucose remains poorly controlled; For reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2DM with cardiovascular disease.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Semaglutide is a <strong>GLP-1 receptor agonist</strong> utilized in pharmaceutical manufacturing. Its core synthesis involves solid-phase peptide chemistry. The molecular formula is C<sub>37</sub>H<sub>69</sub>N<sub>11</sub>O<sub>12</sub>, with CAS No. 910463-68-2.</p>
<h3>Application</h3>
<ul>
<li><strong>Treatment of Type 2 Diabetes:</strong> Regulates blood glucose levels and insulin secretion.</li>
<li><strong>Obesity Management:</strong> Facilitates weight loss through appetite suppression.</li>
<li><strong>Clinical Research:</strong> Investigated for cardiovascular risk reduction in metabolic disorders.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Strictly store at 2°C to 8°C to maintain stability and prevent degradation of the peptide structure.</p>